Vor Biopharma Inc. Stock Split Ratio
Vor Biopharma Inc. (VOR) reported Stock Split Ratio of 5.00% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2026-08-11
- Vor Biopharma Inc. stockholders' equity note, stock split, conversion ratio for the quarter ending 2026-06-30 was 5.00%, a 0.00% change year-over-year.
- Vor Biopharma Inc. stockholders' equity note, stock split, conversion ratio for the quarter ending 2026-03-31 was 5.00%, a 0.00% change year-over-year.
- Vor Biopharma Inc. stockholders' equity note, stock split, conversion ratio for the quarter ending 2025-09-30 was 5.00%, a 0.00% change year-over-year.
- Vor Biopharma Inc. stockholders' equity note, stock split, conversion ratio for the quarter ending 2025-06-30 was 5.00%, a 0.00% change year-over-year.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio 3 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 6 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 9 month | Stockholders' Equity Note, Stock Split, Conversion Ratio 12 month |
|---|---|---|---|---|
| 2026-06-30 | 5.00% 10-Q · filed 2026-08-11 | 5.00% 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | 5.00% 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | 5.00% 10-Q · filed 2026-08-11 | |||
| 2025-09-30 | 5.00% 10-Q · filed 2025-11-13 | 5.00% 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | 5.00% 10-Q · filed 2026-08-11 | 5.00% 10-Q · filed 2026-08-11 | ||
| 2025-03-31 | 5.00% 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | 5.00% 10-Q · filed 2025-11-13 | |||
| 2024-09-30 | 5.00% 10-Q · filed 2025-11-13 | 5.00% 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | 5.00% 10-Q · filed 2025-11-13 | |||
| 2024-03-31 | 5.00% 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |